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OJstic fibrosis (CF) lung disease is characterized by an excess of elast olytic activity 
in the airways leading to progressive destruction of pulmonary tissue. The objective 
of this trial was to determine the optimal region (bronchial or peripheral) for 
deposition of AAT to achieve superior neutralization of free elastase in the induced 
sputum of CF patients. 
After a 2 week run ha, 52 CF patients (modified intent o treat analysis, FEV1 66% 
pred. (range 29 127), 25.3 years old (range 17 42) were randomized to receive a 
once daily deposition of 25 mg of AAT either into the peripheral (n 28) or 
bronchial (n 24) airways over 4 weeks using the AKITA ® device, connected to a 
Pari nebulizer. The primary endpoint was free elastase ha induced sputum. 
No significant differences between the two modes of deposition were observed for 
free elast ase, AAT concentrations, Pseudomonas load, neutr ophil percentages, total 
IgG fragments in induced sputum or FEV v The overall effect of inhaled AAT was 
explored by combining the two treatment groups. Four weeks of treatment with 
inhaled AAT increased the concentrations of AAT in induced sputum. The level of 
elast ase, percentage ofneutr ophils and Pseudomonas counts were reduced. 
Four weeks of inhaled treatment, depositing 25 mg of AAT once daily either 
centrally or peripherally into the lungs of CF patients reduced the levels of free 
elast ase, percentage ofneutrophils and Pseudomonas count. Although no substantial 
effects of the deposition site of AAT were observed, the data s~aggest that, overall, 
inhaled AAT has anti inflammatory effects under the conditions investigated. 
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ANTI-PSEUDOMONAS IgY is now licensed for Prophylaxis and 
Treatment of CF Patients in Sweden 
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ANTI-PSEUDOMONAS lgY (anti PA IgY) is effective for prevention of 
pseudomonas aeruginosa (PA) infections in patients with Cystic Fibrosis (CF) 
(Pediatric Pulmonology 2C~33). Hens vaccinated with PA produce specific anti PA 
IgY. It inhibits adhesion of PA to epithelial cells. Oral IgY does not activate any cell 
activators or mediators of inflammation. IgY is generally recognized as safe for use 
as human food (U S Code of Federal Regulations). Pathogens will not develop 
resistance against IgY and humans do not produce anti IgY antibodies against orally 
administered IgY. 
Specific anti-PA lgY to Cystic Fibrosis: Infections with FA cecur in virtually all 
CF patients and they are the major cause of morbidity and mortality in CF. PA is 
impossible to eradicate from a patient with chronic colonization. Our study on anti 
PA IgY for patients with CF has gone on for 10 years. Thirteen CF patients have 
gargled aily with anti PA IgY; altogether for about 80 patient years. In Nov. 2C~33 
the Swedish Medical Products Agency granted license for anti PA IgY to CF 
patients on the same indication as in our earlier study, provided that observations for 
effect and adverse vents continued. Results: The frequency of positive PA cultures 
over the 10 years is still about 1/40 months of treatment and the need of antibiotics 
is still decreased. Only 1 patient has become cbronically colonized with a non 
mucoid PA. All patients continue to do well without deterioration of pulmonary 
functions and have very few days of sickness. No cultures have sbown any B. 
cepacia (BC), and none have got any infections with Asper~iIIus furnigatus 
probably due to reduced use of antibiotics. Condttsion: Anti PA IgY is a valuable 
drug for prevention and early treatment of PA. 
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Aim: Met enkepbalin is an endogenous opioid pentapeptide with cytokine 
properties that has been investigated ha many ha vitro and in viva models of 
inflammation. This study was conducted in order to examine the possible effect of 
met enkephalin on changes ha pulmonary function provoked by histamine. 
Methods: Experimental animals were Hartley guinea pigs (6 animals per group, 
male female 1:1, weight 5CO 7COg). Classic Konzett and R6ssler's method of whole 
body plethysmography modified by Gjuris was applied to monitor changes in the 
respiratory rate, type of respirations or amplitude of respirations. 
Bronchoconstriction was induced in anesthetized animals by i.v. histamine 
(10btg/kg) and the protective effect of met enkephalin was defined as the 
percentage of histamine blockade (the reduction of histamine induced broncho 
constriction; each animal its own control). Three doses of met enkephalin were 
applied: 0.1 mg/kg, 1 mg/kg, and 10 mg/kg. Data were compared by t test. 
Results: Met enkephalin doses of 1 mg/kg and 10 mg/kg caused significant 
reduction of the histamine induced bronchceonstriction (p<0.059 and p<0.CO9, 
respectively), while the dose of 0.1 mg/kg was ineffective (p~).141). 
Conclusion: Results implicate that met~enkephalin modulates histamine ffects ha 
guinea pig lungs in a dose dependent way. Histamine is not only a 
bronchceonstrictor; it is nowadays recognized as a mediator of ilfflammation and 
part of a complex, not fully under slood network of cytokines and chemokines. This 
fact, together with our results and the previously demonstrated regulating effect of 
met enkephalin on growth of P. aeruginosa nd S. aureus, justify further 
investigation of met enkephalin as a potential drug in treatment of cystic fibrosis. 
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Unfractionated heparin reduces the elasScity and yield stress of CF 
sputum 
V. Br ought on Head 1, M. Carroll 2, J. Shute 1
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Elastic contributions dominate the viscoelastic properties of CF sputum. Our aim 
was to investigate the effect of tmfractionated heparin (UFH) on the theological 
properties of CF sputum from adult patients receiving DNase therapy and DNase 
naive patients. 
Sputa were gently homogenised using a 5ml syringe, then treated with UFH (1 10 
mg/ml) or PBS for lh at 37°C. Rheology was performed using the AR 2CO0 
controlled stress rheometer iTA Instruments Ltd). Using an applied stress of 0.01 
Pa, which was in the linear viscoelastic region, the elasticity (G') and dynamic 
viscosity 0I ')  were determined in the frequency range 0.1 10 Hz. The 
homogenisation pr c~edure was validated by comparing parameters for 3 portions of 
a homogenised sample, with 3 non homogenised portions of the same sample. 
Homogenisation significantly reduced the coefficient of variation in the 
measurements, without altering the viscoelastic parameters measured. 
Values for elasticity and viscosity in sputa from patients on DNase therapy were not 
significantly lower than samples from DNase naive patients. UFH (lmg/ml) 
treatment of samples from patients not on DNase therapy significantly (p<0.05) 
reduced values for elasticity (2.81 (0.93 194.3) Pa), but not viscosity (1.03 (0.28 
141.1) Pa.s), compared to PBS treated samples (elasticity 5.05 (1.607.69) Pa, 
viscosity 1.42 (0.56 2.07) Pa.s) at 0.16 Hz. This was confirmed by a significant 
increase in tan 5 (viscosity/elasticity). UFH had no effect on samples from DNase 
treated patients. UFH also significantly reduced the yield stress in samples from 
patients not on DNase, with no effect on samples from DNase treated patients. 
In conclusion, UFH has mucoactive properties that indicate it may be useful as an 
inhaled therapy to improve cough clearance. 
